Search for: "Mylan Pharmaceuticals"
Results 501 - 520
of 739
Sort by Relevance
|
Sort by Date
13 Feb 2011, 9:08 pm
Mylan Pharmaceuticals Inc. et al. 1:11-cv-00127; filed February 10, 2011 in the District Court of Delaware • Plaintiffs: Novartis Pharmaceuticals Corp.; Novartis AG • Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc. [read post]
8 Feb 2011, 10:51 pm
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey: Court precludes jury… [read post]
3 Feb 2011, 2:11 pm
Mylan Pharmaceuticals., Inc., 696 F. [read post]
2 Feb 2011, 3:52 am
Highlights this week included: India, South Africa gain from J&J generic deal, Patent Pool loses out (Spicy IP) (KEI) Advair (Fluticasone propionate, Salmeterol) – Netherlands: GSK reverse on Dutch Advair patent and SPC (The SPC Blog) (The SPC Blog) (Kluwer Patent Blog) Brazilian Attorney General of the Union restricts ANVISA’s role in pharmaceutical patent review (PatentlyBIOtech) Please join the discussion by adding your comments on any of these stories, and please do let… [read post]
25 Jan 2011, 10:58 pm
General GSK critiques Anti-Counterfeiting Trade Agreement (IP Watch) WHO Members show dismay at delay on Counterfeit Medicines Group (IP Watch) WHO R&D financing committee approved with controversial industry expert (IP Watch) (KEI) (KEI) (KEI) BioCentury this week explores orphan drugs with HP&M attorney and NORD Board Chair (FDA Law Blog) EU: Paediatric extensions and transitional provisions: a question of timing (The SPC Blog) India: Patent Office continue refusing pharmaceutical… [read post]
24 Jan 2011, 8:19 pm
., Mylan, Inc., Teva Pharmaceutical Industries, and UDL Laboratories, Inc. [read post]
21 Jan 2011, 6:38 am
Senate (see our previous posts here and here) critical of the Agency’s recent characterization of the 12-year reference product exclusivity period provided by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”) as “marketing exclusivity” rather than “data exclusivity,” several generic drug manufacturers (Hospira, Momenta Pharmaceuticals, Hospira, Mylan Labs, Teva Pharmaceuticals, and Watson… [read post]
19 Jan 2011, 2:00 am
– Health Care Reform Bill (Patent Baristas) US: Academic study supports longer data exclusivity term for conventional drugs (Patent Docs) US: PTO sued after denying ‘mildly tardy’ second interim PTE request: Genetics & IVF Institute v Kappos (FDA Law Blog) US: AMP v USPTO – Appellees’ brief (Patent Docs) Products Avodart (Dutasteride) – US: GlaxoSmithKline file patent infringement complaint against Anchen following Para IV certification (Patent Docs)… [read post]
16 Jan 2011, 9:48 pm
The manufacturers that filed the appeals case were: Teva Pharmaceutical Industries, Mylan Inc.'s UDL Laboratories and Actavis Inc. [read post]
31 Dec 2010, 3:57 am
Mylan has been sued by several other states, and last year pharmaceutical companies Mylan, AstraZeneca, and Johnson & Johnson agreed to pay $124 million in settlement of claims that the companies violated the U.S. [read post]
31 Dec 2010, 2:46 am
Mylan has been sued by several other states, and last year pharmaceutical companies Mylan, AstraZeneca, and Johnson & Johnson agreed to pay $124 million in settlement of claims that the companies violated the U.S. [read post]
29 Dec 2010, 2:57 am
Ferring Pharmaceuticals, Inc et al. [read post]
28 Dec 2010, 10:58 am
Caraco Pharmaceutical Laboratories, Ltd., 601 F.3d 1359 (Fed. [read post]
22 Dec 2010, 3:01 am
Mylan Inc. et al. [read post]
17 Dec 2010, 7:47 am
(Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. [read post]
14 Dec 2010, 6:12 pm
One products liability lawsuit was originally filed by Gladys Mensing, who is suing Teva Pharmaceutical Industries Ltd., Mylan Inc., and Actavis Group. [read post]
8 Dec 2010, 2:20 am
(America-Israel Patent Law) Ziagen (Abacavir) – US: Mylan’s Matrix receives tentative FDA approval under PEPFAR for Abacavir Sulfate tablets, 60 mg (SmartBrief) [read post]
1 Dec 2010, 12:15 am
General Australia: Gene patents survive Australian Senate enquiry – for now (Patentology) China: Why China is preferred over India by the US pharmaceutical industry (IP Dragon) China: Parasiting trademarks of drugs in China breeds resistant malaria parasite (IP Dragon) EU guidelines clear way for biosimilar antibodies (GenericsWeb) EU: SPCs and the ‘salt’ problem no 2 (The SPC Blog) UK: Cephalon v Orchid – a path less clear? [read post]
24 Nov 2010, 12:37 am
General Global pharmaceutical linkage regulations: A consortium framework (IP Osgoode) Pfizer rolling out generics to grab off-patent market (GenericsWeb) Australia: Too little too late: CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) and the judicial discretion to amend a patent (IP Whiteboard) Brazil: You lost your chance! [read post]
11 Nov 2010, 12:54 pm
Mylan Pharmaceuticals, Inc., 2010 WL 3339274, at *3 (W.D. [read post]
